To assess potential benefits associated with both intermittent (use for 3 weeks, remove for 1 week, as defined in the package insert) and continuous (use for 4 weeks, then replace) CVR use among women either with BV or at high risk for BV. The investigators will also recruit women who are HSV2-infected.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
81
UW Virology Research Clinic
Seattle, Washington, United States
Quantity of BV-associated Bacteria by qPCR and High-throughput Sequencing Tests
Change in Log10 quantity of bacteria detected (L. crisptatus, L. jensenii, L. iners, G. vaginalis, Megasphaera spp. BVAB2)
Time frame: Up to 8 months
Number of Visits With BV
Number of visits with BV prior to use of NuvaRing CVR compared to during NuvaRing CVR use.
Time frame: Up to 8 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.